Diagnostic stocks: six stocks in check

Frankfurt, Düsseldorf Few industries have benefited as much from the corona pandemic as the manufacturers of the aids with which an infection with the Sars-CoV-2 virus can be detected. The enormous demand for both PCR and rapid tests has given them an unprecedented boom in the past year and a half.

Many experts originally expected that the Covid diagnostics business would normalize again in the second half of the year at the latest. At the time, the idea prevailed that the pandemic would be over in the course of the year.

But in view of the still high number of infections and the new Omikron variant of the Covid-19 virus, it is now becoming apparent that the demand for tests will remain high for the time being and that the diagnostics boom is likely to continue beyond 2021. That makes the detailed look at individual stocks interesting.

Sales and profits increase